NOS3 and diabetes mellitus: As reported, CavNOxin could attenuate total aortic plaque up to 70% in diabetic apolipoprotein E knockout (ApoE−/−) mice, a well-established model of experimental atherosclerosis, whereas mice lacking eNOS show resistance to CavNOxin treatment, suggesting endogenous eNOS activation can provide atheroprotection in diabetes (12).